| Date | Acquired company | Acquiring company | Amount | Related |
|---|---|---|---|---|
| 2013-08-26 | Zymenex (Denmark) | Chiesi (Italy) | Rare diseases |
|
| 2013-08-05 | ProFibrix (The Netherlands) | The Medicines Company (USA) | up to $250 million (€188 million) | hemostasis |
| 2013-07-31 | Ceptaris Therapeutics (USA) | Actelion (Switzerland) | Rare diseases |
|
| 2013-07-30 | Precos (UK) | Crown Bioscience (USA) | undisclosed | services |
| 2013-07-29 | Elan (Ireland) | Perrigo (USA) | $ 8.6 billion (€ 6.47 billion) | biopharmaceuticals |
| 2013-07-26 | Antitope (UK) | PolyTherics (UK) | £13.5 million | Technology - Services |
| 2013-07-15 | Syntaxin (UK) | Ipsen (France) | up to €130 million or more depending on the achievement of development and commercial milestones | Endocrine diseases |
| 2013-07-11 | Phlogo (Denmark | Serodus (Norway) | Cardiovascular diseases |
|
| 2013-07-03 | Creapharm (France) | EP Finance Group | undisclosed | production |
| 2013-07-02 | Constitution Medical Investors (USA) | Roche (Switzerland) | $ 220 million and further contingent payments depending on the achievement of certain milestones | diagnostic |
| 2013-07-02 | Protagen Protein Services (Germany) | Zukunftsfond Heilbronn (Germany) | undisclosed | |
| 2013-07-01 | Dualsystems Biotech (Switzerland) | Hybrigenics (France) | undisclosed | services |
| 2013-06-28 | Fresenius Biotech (Germany) | Fuhrer family, owners of Neopharm (Israel) | undisclosed | Biotechnology |
| 2013-06-25 | Cross Pharma (Sweden) | Unimedic (Sweden) | 125 MSEK (€14.2 million) | parallel import |
| 2013-06-24 | immuno-monitoring activities of Indicia Biotechnology (France) | Platine Pharma Services (France) | immuno-monitoring services |
|
| 2013-06-19 | Ricerca Biosciences’ pharmaceutical services business (France) | WIL Research (USA) | undisclosed | Manufacturing |
| 2013-06-17 | 80 % stake in Activartis (Austria) | group of private investors | Cancer - Oncology |
|
| 2013-06-17 | MicroDose Therapeutx (USA) | Teva Pharmaceutical Industries (Israel) | up to $125 million | Respiratory diseases |
| 2013-06-17 | Aragon Pharmaceuticals (USA - CA) | Johnson&Johnson (J&J) (USA - NJ) | up to $ 1 billion | Cancer - Oncology |
| 2013-06-10 | Pearl Therapeutics (USA) | AstraZeneca (UK) | up to $1.15 billion | Respiratory diseases |
